OFTALMOLOGIE pro praxi / 2019

SOLEN |  23 LITERATURA 1. Chalam KV, Brar VS, Murthy RK. Human ciliary epithelium as a source of synthesis and secretion of vascular endothe- lial growth factor in neovascular glaucoma. JAMA Ophthal- mol 2014; 132(11): 1350–1354. 2. Kaur C, Foulds WS, Ling E‑A. Hypoxia‑ischemia and retinal ganglion cell damage. Clin Ophthalmol 2008; 2(4): 879–889. 3. Kim M, Lee C, Payne R, Yue BYJT, Chang J‑H, Ying H. An- giogenesis in glaucoma filtration surgery and neovascular glaucoma: a review. Surv Ophthalmol 2015; 60(6): 524–535. 4. Ng EWM, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP. Pegaptanib, a targeted anti‑VEGF aptamer for ocu- lar vascular disease. Nat Rev Drug Discov 2006; 5(2): 123–132. 5. Narayanan R, Kuppermann BD, Jones C, Kirkpatrick P. Rani- bizumab. Nat Rev Drug Discov 2006; 5(10): 815–816. 6. De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med 2012; 44(1): 1–9. 7. Stewart MW, Grippon S, Kirkpatrick P. Aflibercept. Nat Rev Drug Discov. 2012; 11(4): 269–270. 8. EllisLM.Bevacizumab.NatRevDrugDiscov.2005;Suppl:S8–S9. 9. Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 2007; 85(4): 425–430. 10. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibi- zumab and bevacizumab. Angiogenesis 2012; 15(2): 171–185. 11. Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Kru- mmen L, et al. Humanization of an anti‑vascular endothelial growth factor monoclonal antibody for the therapy of solid tu- mors and other disorders. Cancer Res 1997; 57(20): 4593–4599. 12. Yang J, Wang X, Fuh G, Yu L, Wakshull E, Khosraviani M, et al. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Mol Pharm 2014; 11(10): 3421–3430. 13. Yu L, Liang XH, Ferrara N. Comparing protein VEGF inhi- bitors: In vitro biological studies. Biochem Biophys Res Com- mun 2011; 408(2): 276–281. 14. Ahn SJ, Ahn J, Park S, Kim H, Hwang DJ, Park JH, et al. In- traocular pharmacokinetics of ranibizumab in vitrectomi- zed versus nonvitrectomized eyes. Invest Ophthalmol Vis Sci 2014; 55(1): 567–573. 15. Niwa Y, Kakinoki M, Sawada T, Wang X, Ohji M. Ranibizumab and aflibercept: intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaqueeyes. InvestOphthalmolVisSci2015;56(11):6501–6505. 16. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular phar- macokinetics of bevacizumab after a single intravitreal in- jection in humans. Am J Ophthalmol 2008; 146(4): 508–512. 17. Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharma- cokinetics of ranibizumab following a single intravitreal injec- tion in humans. Am J Ophthalmol 2012; 154(4): 682–686.e2. 18. Do D. Oral presentation at 11th Congress of the Asia‑Pacific Vitreo‑retina Society (APVRS); Kuala Lumpur, Malay- sia, December 2017: 8–10. 19. Stewart MW. Pharmacokinetics, pharmacodynamics and pre‑clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol 2014; 7(2): 167–180. 20. Fauser S, Schwabecker V, Muether PS. Suppression of in- traocular vascular endothelial growth factor during afliber- cept treatment of age‑related macular degeneration. Am J Ophthalmol 2014; 158(3): 532–536. 21. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, SeeR,etal.Systemicpharmacokinetics following intravitreal in- jectionsofranibizumab,bevacizumaboraflibercept inpatients withneovascularAMD.BrJOphthalmol2014;98(12):1636–1641. 22. Seddon JM, Chen CA. The epidemiology of age‑related macular degeneration. Int Ophthalmol Clin 2004; 44: 17–39. 23. StudničkaJ.Ranibizumab (Lucentis)v léčběvěkempodmíně- némakulární degenerace. Čes. a slov. Oftal. 2009; 65(3): 107–111 24. Berger JW, Fine SL, Maguire MG. Age‑related Macular De- generation. Mosby, Inc., New York, 1999: 463 s. 25. Boguszaková J. Věkem podmíněná makulární degenera- ce. Prakt Lék 2001; 81: 310–314. 26. Landy J, Brown GC. Update on Photodynamic Therapy. Curr Opin Ophthalmol 2003; 14: 163–168. 27. Visudyne®, product monograph, third edition, Chameleon Medical Communications Ltd, London, 2003: 92 s. 28. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascu- lar agerelated macular degeneration. N Engl J Med 2006; 355 (14): 1432–1444. 29. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age‑related macular degeneration. N Engl J Med 2006; 355(14): 1419–1431. 30. Spaide R. Ranibizumab according to need: a treatment for agerelated macular degeneration. Am J Ophthalmol 2007; 143(4): 679–680. 31. Brown DM, Regillo CD. Anti‑VEGF agents in the treatment of neovascular age‑related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007; 144(4): 627–637. 32. Řehák J, Studnička J. Doporučené postupy pro diagnos- tiku a léčbu pacientů s venózní okluzí sítnice. Čes. a slov. Of- tal. 2012; 68(6): 244–256. 33. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P. Ranibizumab for macular edema due to retinal vein oc- clusions: long‑term follow‑up in the HORIZON trial. Ophthal- mology 2012; 119(4): 802–809. 34. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG. Sustained benefits from ranibizu- mab for macular edema following central retinal vein occlu- sion: twelve‑month outcomes of a phase III study. Ophthal- mology 2011; 118(10): 2041–2049. 35. Pielen A, Clark WL, Boyer DS, et al. Integrated results from the COPERNICUS and GALILEO studies. Clin Ophthal- mol 2017; 11: 1533–1540. 36. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal afli- bercept for macular edema following branch retinal vein oc- clusion: the 24-week results of the VIBRANT study. Ophthal- mology 2015; 122(3): 538–544. 37. Chen E, Looman M, Laouri M, et al. Burden of illness of dia- betic macular edema: literatura review. Curr Med Res Opin 2010; 26: 1587–1597. 38. Studnička J. Aflibercept v léčbě diabetického makulární- ho edému. Čes. a slov. Oftal. 2015; 71(5): 243–246. 39. Sosna T, Švancarová R, Netuková M, et al. Současný pohled na diabetický makulární edém. Čes a slov Oftal 2012; 3: 91–96. 40. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabe- tic macular edema (RESOLVE Study): a 12-month, randomi- zed, controlled, double‑masked, multicenter phase II study. Diabetes Care 2010; 33(11): 2399–2405. 41. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthal- mology 2009; 116(11): 2175–2181.e1. 42. Korobelnik J‑F, Do DV, Schmidt‑Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121(11): 2247–2254. 43. Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE Study Group. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularizati- on secondary to pathologic myopia. Ophthalmology 2014; 121(3): 682–692.e2. 44. Lai TYY, Staurenghi G, Lanzetta P, et al. MINERVA stu- dy group. Efficacy and safety of ranibizumab for the trea- tement of choroidal neovascularization due to uncommon cause: Twelve‑Month Results of the MINERVA Study. Retina 2018; 38(8): 1464–1477. 45. Al‑Latayfeh M, Silva PS, Sun JK, Aiello LP. Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harb Per- spect Med 2012; 2(6): a006411–a006411. 46. Bahar I, Yeung SN, Sella R, Slomovic A. Anterior seg- ment uses of bevacizumab. Curr Opin Ophthalmol 2012; 23(4): 303–316. 47. Xiong Q, Li Z, Li Z, Zhu Y, Abdulhalim S, Wang P, et al. Anti‑VEGF agents with or without antimetabolites in trabe- culectomy for glaucoma: a meta‑analysis. PLoS ONE 2014; 9(2): e88403. 48. Al‑Latayfeh M, Silva PS, Sun JK, Aiello LP. Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harb Per- spect Med 2012; 2(6): a006411–a006411. KNIŽNÍ NOVINKA Radkin Honzák VŠICHNI ŽIJEM V BLÁZINCI „Všichni žijem v blázinci,“ tvrdí renomovaný psychiatr a psychoterapeut Radkin Honzák, muž vzdělaný a také vtipný, který už padesát let naslouchá lidským strastem. V rozhovorech s novinářkou Renatou Červenkovou se zamýšlí nad způsobem života, který dnes vedeme, i nad stavem společnosti, v níž duchovní rozvoj výrazně pokulhává za technic- kým. Co nám to přinese? Opravdu nám psychofarmaka pomohou k pocitu štěstí? Nejsou některé nové choroby spíš zlozvyky? Proč se mlčí o odvrácené straně papírových plen? Je psychoterapie léčba, nebo ztracený čas? Je pravda, že u vesla jsou te psychopati? Proč umíráme v nemocnicích – tedy tam, kde nechceme? Témata jednotlivých rozhovorů nejsou příliš povzbudivá, Radkin Honzák se jich ale ujímá s nadhledem a s lehkou ironií a vtipně komentuje fenomény dnešní doby, které se, jak říká, „příčí Matce přírodě a psychiatrům zajišťují dostatek pacientů i do budoucna“. Vyšehrad 2018, 216 str., formát 130 × 220 mm, vazba vázaná